● Recruiting

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Condition: Pulmonary Fibrosis · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

PhasePhase 1

Planned participants20

Who can joinAll sexes, 18 Years to 45 Years

Healthy volunteersYes

About this study

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Ruifang Guan · +86-0518-82342973 · ruifang.guan.rg1@hengrui.com

Ye Xu · +86-0518-82342973 · ye.xu.yx1@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tangdu Hospital, Fourth Military Medical University

Xi’an, Shanxi, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07229716